Sugi Predict

Sugi Predict / Compounds / SCHEMBL10248657

SCHEMBL10248657

SCHEMBL10248657

CC(C)(C)C(=O)Nc1ccc(F)c(F)c1C(O)c1ccncc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ RAF1 P04049 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.35
▸ TSHR P16473 1/20 0.34
▸ HTT P42858 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ TP53 P04637 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CETP P11597 1/20 0.34
▸ RAB9A P51151 2/20 0.33
▸ TOP2A P11388 1/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10248576 0.86 SMN1; SMN2 (0.44) L3MBTL1KDM4EKMT2AALDH1A1TSHR
SCHEMBL30937617 0.80 ALDH1A1 (0.41) L3MBTL1KDM4EKMT2AALDH1A1HTT
SCHEMBL10252235 0.75 L3MBTL1 (0.42) L3MBTL1KDM4EKMT2ATSHRHTT
SCHEMBL28413 0.75 KMT2A (0.44) L3MBTL1KDM4EKMT2ARAF1ALDH1A1
SCHEMBL10533579 0.74 CETP (0.47) L3MBTL1KDM4ERAF1ALDH1A1TSHR
SCHEMBL14809422 0.73 ALDH1A1 (0.39) L3MBTL1KDM4EKMT2AHSD17B10ALDH1A1
SCHEMBL30937653 0.69 L3MBTL1 (0.44) L3MBTL1KDM4EKMT2AALDH1A1HTT
SCHEMBL2079331 0.68 ALDH1A1 (0.47) L3MBTL1KDM4EALDH1A1TSHRSMN1; SMN2
SCHEMBL29952711 0.67 L3MBTL1 (0.42) L3MBTL1KDM4EKMT2AALDH1A1HTT
SCHEMBL1642548 0.67 TSHR (0.46) L3MBTL1KDM4EALDH1A1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 — — US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 — — US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 — — US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 — — US disclosed
US-8211896-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2012-07-03 — — US disclosed
US-8211896-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2012-07-03 — — US disclosed
US-20120014997-A1 ARYL SULFONAMIDES UNGASHE SOLOMON (US) 2012-01-19 — — US disclosed
US-20120014997-A1 ARYL SULFONAMIDES UNGASHE SOLOMON (US) 2012-01-19 — — US disclosed
US-20110021523-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2011-01-27 — — US disclosed
US-20110021523-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2011-01-27 — — US disclosed
US-7582661-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2009-09-01 — — US disclosed
US-7582661-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2009-09-01 — — US disclosed
US-20090163498-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-06-25 — — US disclosed
US-20090163498-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-06-25 — — US disclosed
US-20090118307-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-05-07 — — US disclosed
US-20090118307-A1 Aryl Sulfonamides CHEMOCENTRYX, INC. (US) 2009-05-07 — — US disclosed
US-20080293717-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2008-11-27 — — US disclosed
US-20080293717-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2008-11-27 — — US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 — — US disclosed
US-7420055-B2 Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide CHEMOCENTRYX, INC. (US) 2008-09-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118307-A1 Aryl Sulfonamides CCR9, CCR1, CCR2 L3MBTL1 3021/4885KDM4E 3023/4885KMT2A 2760/4885
US-10364240-B2 Aryl sulfonamides CCR9, CCR1, CCR2 L3MBTL1 3021/4885KDM4E 3023/4885KMT2A 2760/4885
US-20120014997-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 L3MBTL1 3021/4885KDM4E 3023/4885KMT2A 2760/4885
US-20110021523-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 L3MBTL1 3021/4885KDM4E 3023/4885KMT2A 2760/4885
US-20150080351-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 L3MBTL1 3021/4885KDM4E 3023/4885KMT2A 2760/4885
US-20090163498-A1 Aryl Sulfonamides CCR9, CCR1, CCR2 L3MBTL1 3021/4885KDM4E 3023/4885KMT2A 2760/4885
US-20080293717-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 L3MBTL1 3021/4885KDM4E 3023/4885KMT2A 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.